Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antoniotti C, Ambrosini M, Piva VM, Nichetti F, Fassan M, Cremolini C, Lonardi S. Pietrantonio F, et al. Among authors: de grandis mc. Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20. Eur J Cancer. 2023. PMID: 37924647 Free article.
The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer.
Procaccio L, Bergamo F, Gatti M, Chiusole B, Tierno G, Bergo E, Daniel F, Nappo F, Maddalena G, Rasola C, Barsotti G, De Grandis MC, Piva VM, Rizzato MD, Sergi G, Brunello A, Zagonel V, Lonardi S. Procaccio L, et al. Among authors: de grandis mc. Eur J Cancer. 2022 Dec;177:112-119. doi: 10.1016/j.ejca.2022.09.023. Epub 2022 Oct 7. Eur J Cancer. 2022. PMID: 36335781 Free article.
ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
Piva VM, De Grandis MC, Zuin IS, Angerilli V, Nappo F, Alfieri R, Ahcene Djaballah S, Murgioni S, Bergamo F, Fassan M, Valmasoni M, Lonardi S. Piva VM, et al. Among authors: de grandis mc. Updates Surg. 2023 Feb;75(2):305-312. doi: 10.1007/s13304-022-01379-2. Epub 2022 Oct 22. Updates Surg. 2023. PMID: 36272058 Review.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Soldà C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F. Rimini M, et al. Among authors: de grandis mc. Liver Int. 2024 May;44(5):1108-1125. doi: 10.1111/liv.15885. Epub 2024 Mar 22. Liver Int. 2024. PMID: 38517286